Getting to the right Clone Faster: New Approaches to complex Gibson Assemply

Gibson Assembly changed molecular cloning. Seamless, sequence-independent, and simple, it became the method of choice across research applications, and it remains the right framework for the vast majority of cloning projects today. As the constructs researchers are building grow more ambitious, however, so does the opportunity to push the method further: more fragments, more design flexibility, and faster paths to sequence-verified constructs.

In this webinar, Jasmine Hershewe, PhD, Chief Scientific Officer at Racer Biosciences, will explore how to get to correct constructs faster, particularly as complexity increases. Drawing on benchmarking data, she will walk through the design principles, workflow strategies, and reagent innovations behind F1-X™ Next-Gen Gibson Assembly for up to 14-fragment pathway builds. Topics will include how overlap design shapes downstream screening efficiency, how temperature tunability expands the accessible sequence space for challenging builds, and why whole-plasmid fidelity evaluation is becoming the new standard for construct verification.

Whether you are new to Gibson Assembly or use it every week, this session offers a practical framework for thinking about cloning beyond the reaction itself and for approaching multi-fragment builds with the confidence and documentation to back them up.

• Gibson Assembly is the right foundation, and the toolkit around it keeps getting better: Learn how advances in reagent chemistry, overlap design, and workflow documentation are extending what's reliably achievable, from routine builds all the way through complex, multi-fragment constructs.
• Multi-fragment assembly is more accessible than ever: With the right design principles and validated protocols, high-fidelity assembly at 4, 7, even 11+ fragments is within reach for any lab already comfortable with Gibson Assembly.
• Faster paths to the right clone start with smarter design: Discover how bioinformatic tools, temperature tunability, optimized enzyme ratios, stabilizer chemistry, and whole-plasmid fidelity evaluation work together to reduce screening burden and lower the true cost per correct construct.